|Day Low/High||19.00 / 19.57|
|52 Wk Low/High||12.55 / 21.25|
Horizon Pharma plc (NASDAQ:HZNP) announced new data from the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) showing a majority of patients that had reductions in proptosis at week 24...
A prospective longitudinal natural history registry designed to provide long-term data evaluating people living with cystinosis was launched today at a meeting of The North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) in Chicago,...
Horizon Pharma plc (Nasdaq: HZNP) enrolled the first patient in a clinical trial evaluating the use of KRYSTEXXA® (pegloticase injection) with methotrexate to sustain lower serum uric acid (sUA) levels of people living with chronic gout refractory to...
Horizon Pharma plc (NASDAQ: HZNP) will present new data on the 48-week follow up for the Phase 2 clinical trial evaluating teprotumumab for the treatment of moderate-to-severe active thyroid eye disease (TED).
Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conference: Morgan Stanley 16 th Annual Global Healthcare Conference Date: Sept.
Horizon Pharma plc (NASDAQ:HZNP) announced the early completion of enrollment for the confirmatory Phase 3 trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED).
Horizon Pharma plc (NASDAQ: HZNP) announced its second-quarter 2018 financial results today.
Horizon Pharma plc (Nasdaq: HZNP) today announced that the company has been named to PEOPLE's "50 Companies That Care " list for 2018.
Horizon Pharma plc (Nasdaq: HZNP) today announced that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.
Horizon Pharma plc (Nasdaq: HZNP) announced today that its second-quarter financial results will be released on Wednesday, August 8, 2018.
These names are showing bullish and bearish technical patterns over the past week.
The endowment will support a clinical care team dedicated to providing rare disease patients with earlier intervention and more consistent treatment over the course of their lifetimes
Investors in Horizon Pharma plc saw new options begin trading this week, for the May 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 98 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Agreement Aims to Further Expand Growing Gout Franchise
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.